Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1978 Sep;14(3):277–280. doi: 10.1128/aac.14.3.277

In Vitro Studies with UK-18,892, a New Aminoglycoside Antibiotic

S Jevons 1, H E Cheeseman 1, K W Brammer 1
PMCID: PMC352451  PMID: 708005

Abstract

The antibacterial activity of UK-18,892, a new semisynthetic aminoglycoside, was examined against aminoglycoside-susceptible and aminoglycoside-resistant clinical isolates of gram-negative bacilli and Staphylococcus aureus. UK-18,892 had a similar degree of activity to those of amikacin and kanamycin A against aminoglycoside-susceptible bacteria but was less potent than gentamicin against all isolates except Providencia spp. UK-18,892 was highly active against aminoglycoside-resistant bacteria, inhibiting 93% of the 268 isolates examined at 12.5 μg/ml. Amikacin was similarly active, whereas gentamicin inhibited only 14% of these isolates at 12.5 μg/ml.

Full text

PDF
277

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Scheife R. T. Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics--part 4: aminoglycosides. Am J Hosp Pharm. 1977 Jul;34(7):723–737. [PubMed] [Google Scholar]
  2. Levison M. E., Kaye D. In vitro comparison of four aminoglycoside antibiotics: sisomicin, gentamicin, tobramycin, and BB-K8. Antimicrob Agents Chemother. 1974 Jun;5(6):667–669. doi: 10.1128/aac.5.6.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Phillips I., King B. A., Shannon K. P. The mechanisms of resistance to aminoglycosides in the genus Pseudomonas. J Antimicrob Chemother. 1978 Mar;4(2):121–129. doi: 10.1093/jac/4.2.121. [DOI] [PubMed] [Google Scholar]
  4. Price K. A., Chudzik G. M. Amikacin. Lancet. 1977 Sep 24;2(8039):659–660. doi: 10.1016/s0140-6736(77)92523-5. [DOI] [PubMed] [Google Scholar]
  5. Rahal J. J., Jr, Simberkoff M. S., Kagan K., Moldover N. H. Bactericidal efficacy of Sch 20569 and amikacin against gentamicin-sensitive and -resistant organisms. Antimicrob Agents Chemother. 1976 Apr;9(4):595–599. doi: 10.1128/aac.9.4.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Reynolds A. V., Hamilton-Miller J. M., Brumfitt W. Newer aminoglycosides--amikacin and tobramycin: an in-vitro comparison with kanamycin and gentamicin. Br Med J. 1974 Sep 28;3(5934):778–780. doi: 10.1136/bmj.3.5934.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Richardson K., Jevons S., Moore J. W., Ross B. C., Wright J. R. Synthesis and antibacterial activities of 1-N [(S)-omega-amino-2-hydroxyalkyl] kanamycin A derivatives. J Antibiot (Tokyo) 1977 Oct;30(10):843–846. doi: 10.7164/antibiotics.30.843. [DOI] [PubMed] [Google Scholar]
  8. Smith C. R., Baughman K. L., Edwards C. Q., Rogers J. F., Lietman P. S. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977 Feb 17;296(7):349–353. doi: 10.1056/NEJM197702172960701. [DOI] [PubMed] [Google Scholar]
  9. Umezawa H., Doi O., Ogura M., Kondo S., Tanaka N. Phosphorylation and inactivation of kanamycin by Pseudomonas aeruginosa. J Antibiot (Tokyo) 1968 Feb;21(2):154–155. doi: 10.7164/antibiotics.21.154. [DOI] [PubMed] [Google Scholar]
  10. Young L. S., Hewitt W. L. Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother. 1973 Dec;4(6):617–625. doi: 10.1128/aac.4.6.617. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES